(Q36921222)

17 August 2017

1 reference

title

Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations (English)

1 reference

17 August 2017

Gérald J Prud'homme

1

1 reference

17 August 2017

publication date

27 August 2007

1 reference

17 August 2017

published in

Laboratory Investigation

1 reference

17 August 2017

volume

87

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1077-1091

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.3700669

17 August 2017

exact match

0 references

cites work

Transforming growth factor-beta regulation of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Current insights into the role of transforming growth factor-beta in bone resorption.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGFbeta signalling in control of T-cell-mediated self-reactivity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor-beta: innately bipolar

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

IL-17 family cytokines and the expanding diversity of effector T cell lineages

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Latent TGF-beta binding proteins

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Neuropilins in physiological and pathological angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Neuropilin-1: a surface marker of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGFbeta-dependent gene expression profile during maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor type beta induces monocyte chemotaxis and growth factor production

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta receptor signaling is critical for mucosal IgA responses

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Regulation of immune responses by TGF-beta

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta: a mobile purveyor of immune privilege

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Functional dynamics of naturally occurring regulatory T cells in health and autoimmunity.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Oral tolerance: therapeutic implications for autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

1 reference

7 January 2021

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Keratinocyte-fibroblast interactions in wound healing

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Targeting the inflammatory response in healing myocardial infarcts

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta signaling in vascular fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGFbeta, cardiac fibroblasts, and the fibrotic response

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Scar wars: is TGFbeta the phantom menace in scleroderma?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Smad3 signaling involved in pulmonary fibrosis and emphysema

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta signaling: positive and negative effects on tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Role of transforming growth factor-beta in cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor-beta in cancer and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

A delicate balance: TGF-beta and the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The type III TGF-beta receptor suppresses breast cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta and epithelial-to-mesenchymal transitions

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF beta inhibition for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta in cancer and as a therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

A multigenic program mediating breast cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta inhibitors for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibitors of the TGF-beta superfamily and their clinical applications

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition of ALK5 as a new approach to treat liver fibrotic diseases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Anti-TGF-beta strategies for the treatment of chronic liver disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Fibrogenesis in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Role of transforming growth factor-beta in the progression of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Reversal of tumor-induced immunosuppression by TGF-beta inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The inhibition mechanism of histamine release by N-(3,4-dimethoxycinnamoyl) anthranilic acid

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

A double blind controlled trial of N-(3',4'-dimethoxycinnamoyl) anthranilic acid on children with bronchial asthma. N-5' Study Group in Children

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

[Effect of tranilast, an anti-allergic drug, on the human keloid tissues]

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition by tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes anf functions of fibroblasts in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor β 1 Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 Rat

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 expression in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Mouse genetic evidence that tranilast reduces smooth muscle cell hyperplasia via a p21(WAF1)-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The role of TGF-beta signaling in myocardial infarction and cardiac remodeling

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Losartan attenuates bleomycin-induced pulmonary fibrosis in rats

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Reversal of renal disease: is it enough to inhibit the action of angiotensin II?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta1: a novel target for cardiovascular pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronectin expression.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Pirfenidone for the treatment of idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Inhibition of ALK5 signaling induces physeal dysplasia in rats

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Anti-tumor effect of N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

The TGFbeta superfamily in cardiovascular biology

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Immune modulation by plasmid DNA-mediated cytokine gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta3 in the treatment of pressure ulcers: a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Mechanism of action and delivery possibilities for TGFbeta1 in the treatment of myocardial ischemia

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

TGF-beta and atherosclerosis in man.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Plasmid-based gene therapy of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700669

7 January 2021

10.1038/LABINVEST.3700669

Identifiers

DOI

1 reference

17 August 2017

1 reference